Truist analyst Karina Rabayeva initiated coverage of Immunome (IMNM) with a Buy rating and $36 price target The company’s lead asset, varegacestat, could deliver superior efficacy with a more convenient dosing regimen compared to the currently approved Ogsiveo in desmoid tumors, the analyst tells investors in a research note. Truist adds that its sees meaningful upside from the upcoming data readout and additional potential from the IM-1021, ROR1 ADC program expected next year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target raised to $33 from $25 at Stephens
- Immunome’s Strategic Clinical Advancements and Financial Alignment Justify Buy Rating
- Immunome, Inc. Reports Q3 2025 Financial Results
- Immunome’s Strategic Advances and Promising Pipeline Justify Buy Rating
- Immunome reports Q3 EPS (65c), consensus (54c)